TITLE

Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration

AUTHOR(S)
Markus Ladewig; Stefanie Karl; Victoria Hamelmann; Hans-Martin Helb; Hendrik Scholl; Frank Holz; Nicole Eter
PUB. DATE
January 2008
SOURCE
Graefe's Archive of Clinical & Experimental Ophthalmology;Jan2008, Vol. 246 Issue 1, p17
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Abstract Background  Our aim was to evaluate the short-term safety and efficacy of combined photodynamic therapy (PDT) with verteporfin and intravitreal bevacizumab in neovascular age-related macular degeneration (AMD). Methods  A prospective non-randomized interventional case series of 30 eyes of 30 patients with choroidal neovascularization (CNV) caused by AMD was studied. All patients were treated with PDT followed by an intravitreal injection of bevacizumab (1.5 mg) on the same day. Ophthalmic evaluations included determination of best-corrected visual acuity by using ETDRS charts. CNV lesion characteristics were determined by fluorescein angiography, and retinal morphology by optical coherence tomography. Review examinations were performed 1, 4, and 12 weeks following treatment. Results  The median ETDRS letter scores increased by 3 letters after 4 weeks and 4.3 letters after 12 weeks. Median central retinal thickness decreased from the baseline by 145 μm (week 1), 205 μm (week 4), and 171 μm (week 12), respectively (P  Conclusions  Short-term results suggest that a single PDT in combination with intravitreal bevacizumab is safe and associated with stabilization of visual acuity and decrease of intraretinal and subretinal fluid accumulation in the macula. Further evaluation of this treatment strategy for neovascular AMD appears warranted.
ACCESSION #
27684309

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics